QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sana-biotech-stock--the-next-100-bagger

Sana Biotech stock soars after outspoken stock promoter Eric Jackson names it as his latest potential "100-bagger."

 wedbush-initiates-coverage-on-sana-biotechnology-with-outperform-rating-announces-price-target-of-5

Wedbush analyst Martin Fan initiates coverage on Sana Biotechnology (NASDAQ:SANA) with a Outperform rating and announces Pr...

 sana-biotechnology-q2-adj-eps-016-beats-021-estimate

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(...

 update-sana-biotechnology-launches-75m-public-offering-of-common-stock-and-pre-funded-warrants

Sana Biotechnology, Inc. (NASDAQ:SANA) ("Sana"), a company focused on changing the possible for patients through engine...

 sana-biotechnology-study-published-in-nejm-shows-hip-modified-islet-cells-function-without-immunosuppression-in-type-1-diabetes-patient

Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Pers...

 how-to-trade-this-150-gainer-chasing-a-cure-for-type-1-diabetes

An update on Sana Biotechnology.

 morgan-stanley-assumes-sana-biotechnology-at-overweight-announces-price-target-of-12

Morgan Stanley analyst Maxwell Skor assumes Sana Biotechnology (NASDAQ:SANA) with a Overweight rating and announces Price Ta...

 jmp-securities-reiterates-market-outperform-on-sana-biotechnology-maintains-5-price-target

JMP Securities analyst Reni Benjamin reiterates Sana Biotechnology (NASDAQ:SANA) with a Market Outperform and maintains $5 p...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION